Old Mutual Global Investors UK Ltd. trimmed its stake in Pfizer Inc. (NYSE:PFE) by 30.2% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,579 shares of the biopharmaceutical company’s stock after selling 6,302 shares during the period. Old Mutual Global Investors UK Ltd.’s holdings in Pfizer were worth $520,000 as of its most recent SEC filing.
Other large investors have also added to or reduced their stakes in the company. Shine Investment Advisory Services Inc. bought a new position in Pfizer during the 2nd quarter valued at about $102,000. Mckinley Capital Management LLC Delaware bought a new position in Pfizer during the 2nd quarter valued at about $103,000. D. Scott Neal Inc. increased its position in Pfizer by 19.3% in the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after acquiring an additional 504 shares in the last quarter. Herndon Capital Management LLC acquired a new stake in Pfizer in the 2nd quarter valued at about $120,000. Finally, Private Vista LLC increased its position in Pfizer by 2,277.3% in the 2nd quarter. Private Vista LLC now owns 199,317 shares of the biopharmaceutical company’s stock valued at $133,000 after acquiring an additional 190,933 shares in the last quarter. 69.87% of the stock is owned by institutional investors.
Shares of Pfizer Inc. (NYSE PFE) traded down $1.94 during midday trading on Monday, reaching $34.67. 40,290,000 shares of the company were exchanged, compared to its average volume of 20,260,000. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43. Pfizer Inc. has a 52-week low of $31.67 and a 52-week high of $39.43. The firm has a market capitalization of $206,660.00, a PE ratio of 9.85, a P/E/G ratio of 2.20 and a beta of 0.94.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.56 by $0.06. Pfizer had a net margin of 40.55% and a return on equity of 26.86%. The firm had revenue of $13.70 billion for the quarter, compared to analyst estimates of $13.67 billion. During the same quarter in the previous year, the firm posted $0.47 earnings per share. The business’s revenue was up .6% on a year-over-year basis. analysts forecast that Pfizer Inc. will post 2.94 EPS for the current year.
Pfizer announced that its board has initiated a stock buyback program on Monday, December 18th that permits the company to buyback $10.00 billion in outstanding shares. This buyback authorization permits the biopharmaceutical company to repurchase shares of its stock through open market purchases. Shares buyback programs are usually a sign that the company’s management believes its stock is undervalued.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd will be given a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.92%. The ex-dividend date is Thursday, February 1st. This is a positive change from Pfizer’s previous quarterly dividend of $0.32. Pfizer’s payout ratio is currently 38.64%.
In other news, EVP Rady A. Johnson sold 8,000 shares of the business’s stock in a transaction on Friday, December 15th. The shares were sold at an average price of $37.07, for a total value of $296,560.00. Following the sale, the executive vice president now owns 46,963 shares of the company’s stock, valued at $1,740,918.41. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Alexander R. Mackenzie sold 6,750 shares of the company’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $37.00, for a total transaction of $249,750.00. Following the sale, the insider now directly owns 103,458 shares in the company, valued at $3,827,946. The disclosure for this sale can be found here. Insiders own 0.06% of the company’s stock.
PFE has been the subject of several research reports. BMO Capital Markets set a $37.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research report on Tuesday, October 10th. Barclays set a $38.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research report on Wednesday, October 11th. Zacks Investment Research cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. Deutsche Bank set a $38.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research report on Wednesday, October 11th. Finally, Jefferies Group set a $38.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a research report on Monday, October 16th. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $39.25.
ILLEGAL ACTIVITY WARNING: “Old Mutual Global Investors UK Ltd. Decreases Position in Pfizer Inc. (PFE)” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/05/pfizer-inc-pfe-shares-sold-by-old-mutual-global-investors-uk-ltd.html.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.